GA-FINEOS-CORPORATION
24.3.2022 14:17:06 CET | Business Wire | Press release
The FINEOS Corporation (ASX:FCL ), the leading core platform for life, accident and health insurance globally, released a set of product updates within the cloud-native FINEOS Platform that provide expanded capabilities across Group, Voluntary, and Absence Management products. The updates fulfil needs throughout the full customer spectrum across insurers, employers, and employees to support sales and service effectiveness, new product speed to market, and an enriched customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005534/en/
To gain deeper insights into the FINEOS Platform Winter Release, join the live product management panel discussion: The FINEOS Platform: Purpose-Built for Innovation and Growth on April 14, 2022 at 11:30 am ET.
"This release marks another significant step forward in how the FINEOS Platform serves all parts of the Group, Voluntary, and Absence value chain. We are solving more problems for our customers and doing so in uniquely seamless ways,” said Eoin Kirwan, Chief Product Officer, FINEOS.
The FINEOS Platform Group, Voluntary, and Absence Management Enhancements Include:
Sales and Underwriting Effectiveness
- Integrated Experience Rating: NextGen functionality for the underwriting and actuarial teams to drive profitability across their book of business. Via an embedded user experience, an underwriter can leverage prior claims experience to provide the best appropriate rate for the customer while providing leading risk management principles for the insurer. The experience rate is blended with the manual rate based upon insurer rules and preferences.
- Enhanced Group Underwriting provides one view of the employer at time of quote: Integrated pricing flexibility and enhanced underwriting processes provides real time adjustment to changing market needs. Whole case underwriting enables optimized product bundles based on the employer’s total need and drives greater enrollment participation.
- LIMRA LDEx API Enhancements: Enhanced LIMRA LDEx APIs include absence management connectivity and data management.
New Product Speed to Market
- Voluntary Benefits Product Enhancements for Policy, Billing, and Claims: Enhanced claims integration and automation capabilities for accident, critical illness, and hospital indemnity enables insurers to leverage integrated eligibility and enrollment data for member elections to drive voluntary product claim acceleration and auto adjudication.
- Additional Member Management and Bill Processing: This release provides extended support for the variety of administrative models across group insurance and worksite for member management.
- Billing Enhancements: Enhanced list bill processing supports the increased consumer centric product and services required by the market with additional billing support for insured Paid Family and Medical Leave (PFML) policies.
Customer Experience
- Robust Employer Dashboard and Reporting Portal and APIs: Real-time data dashboards enable employers to view workforce leave information and review data in graphical views, filter the data by leave reason, groups, and dates. Reports can be exported in Excel or PDF formats to gain insight into individual case details.
- Intermittent Leave Process Improvement: This release reduces friction associated with intermittent leave, including surfacing the right level of information and automation, low-touch, and no-touch options, such as over-frequency tolerance rule.
- Paid Leave Integration: Enriched integration and automation between paid leave, unpaid leave, disability, and voluntary benefits that pertain to an employee’s single leave reason, reduces duplicate work and errors, and providing a single source of truth across the value chain for all elements of an employee’s leave claim.
“As the only purpose-built, cloud-native core insurance solution for the life, accident and health market, the FINEOS Platform remains ahead of the curve in meeting the technical and operational needs of insurers,” said Michael Kelly, CEO, FINEOS. “Deployable as an end-to-end core solution, or as components to enable incremental transformation efforts, the FINEOS Platform has something for the entire Employee Benefits value chain including better support for the sales/service process, the customer experience and the ability to deal with a broad range of products and services such as absence management,” added Kelly.
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest employee benefits insurers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative, progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform is the only purpose-built, end-to-end SaaS insurance solution for the life, accident and health market. The FINEOS AdminSuite delivers industry leading capabilities across core administration including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as one suite. The machine learning enabled FINEOS Engage solution enables robust people first digital engagement pathways and the FINEOS Insight solution provides predictive analytics and reporting across the business.
For more information, visit www.FINEOS.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005534/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
